Background: Orexin (hypocretin) signaling is implicated in drug addiction and reward, but its role in feeding and food-motivated behavior remains unclear.

Methods: We investigated orexin's contribution to food-reinforced instrumental responding using an orexin 1 receptor (Ox1r) antagonist, orexin -/- (OKO) and littermate wildtype (WT) mice, and RNAi-mediated knockdown of orexin. C57BL/6J (n = 76) and OKO (n = 39) mice were trained to nose poke for food under a variable ratio schedule of reinforcement. After responding stabilized, a progressive ratio schedule was initiated to evaluate motivation to obtain food reinforcement.

Results: Blockade of Ox1r in C57BL/6J mice impaired performance under both the variable ratio and progressive ratio schedules of reinforcement, indicating impaired motivational processes. In contrast, OKO mice initially demonstrated a delay in acquisition but eventually achieved levels of responding similar to those observed in WT animals. Moreover, OKO mice did not differ from WT mice under a progressive ratio schedule, indicating delayed learning processes but no motivational impairments. Considering the differences between pharmacologic blockade of Ox1r and the OKO mice, animals with RNAi mediated knockdown of orexin were then generated and analyzed to eliminate possible developmental effects of missing orexin. Orexin gene knockdown in the lateral hypothalamus in C57BL/6J mice resulted in blunted performance under both the variable ratio and progressive ratio schedules, resembling data obtained following Ox1r antagonism.

Conclusions: The behavior seen in OKO mice likely reflects developmental compensation often seen in mutant animals. These data suggest that activation of the Ox1r is a necessary component of food-reinforced responding, motivation, or both in normal mice.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2849869PMC
http://dx.doi.org/10.1016/j.biopsych.2009.12.035DOI Listing

Publication Analysis

Top Keywords

oko mice
20
progressive ratio
16
variable ratio
12
ratio schedule
12
mice
10
orexin
9
orexin receptor
8
knockdown orexin
8
blockade ox1r
8
c57bl/6j mice
8

Similar Publications

Inhibitory effects of the combination of rapamycin with gemcitabine plus paclitaxel on the growth of pancreatic cancer tumors.

Hum Cell

January 2025

Department of Gastroenterology and Hepatology, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505, Japan.

We previously examined the antitumor effects of short interfering RNA nanoparticles targeting mammalian target of rapamycin (mTOR) in an orthotopic pancreatic cancer mouse model. We herein report the inhibitory effects of the mTOR inhibitor rapamycin on tumor growth in a novel established mouse model of pancreatic cancer using human pancreatic cancer cell line-derived organoids. Gemcitabine, 5-fluorouracil, and gemcitabine plus nab-paclitaxel are clinically used to treat advanced pancreatic cancer.

View Article and Find Full Text PDF

Studies with genetically modified mice have implicated the transcriptional regulator STAT3 as a key modulator of bone development. STAT3-OKO knockout mouse lines were generated in two genetic backgrounds, pure C57BL/6 (STAT3-OKO-BL) and mixed C57BL/6, CD1 (STAT3-OKO-M). Both lines exhibited defective postnatal bone development resulting in reduced body weight and shortened femurs that displayed low bone mineral density as well as cortical widening and thinning in the diaphyseal region.

View Article and Find Full Text PDF

There is a high demand for the development of drugs against Alzheimer's disease (AD), which is related to the misfolding and aggregation of Amyloid-β (Aβ), due to the increasing number of patients with AD. In our present study, we aimed to assess the aggregation inhibitory effect of various synthetic YS-peptides on Aβ25-35 to identify an applicable peptide for clinical use for AD treatment and prevention. Suppression and aggregate resolution activities of YS-peptides against Aβ25-35 were evaluated using a Thioflavin T assay and scanning electron microscopy (SEM).

View Article and Find Full Text PDF
Article Synopsis
  • - The MET receptor is crucial for various biological processes, but its dysregulation is linked to cancers like non-small cell lung cancer and renal cancer, highlighting a significant medical need for better treatment options.
  • - Current MET inhibitors face challenges such as resistance and toxicity, particularly in treating brain metastases, which further emphasizes the demand for improved therapies.
  • - Researchers are developing a new class of MET inhibitors designed to effectively target brain tumors and specific cancer mutations, which showed promising results in preclinical models, significantly extending survival in treated animals.
View Article and Find Full Text PDF

Discovery of Potent and Selective Covalent Inhibitors of HER2 and HER2.

J Med Chem

June 2024

Pfizer Boulder Research and Development, Boulder, Colorado 80301, United States.

Article Synopsis
  • * Enhertu is currently the only approved treatment specifically targeting HER2 mutant tumors, but existing Tyrosine Kinase Inhibitors (TKIs) often have unwanted side effects, mainly from inhibiting EGFR.
  • * The objective of this research was to develop a new, potent TKI that effectively inhibits HER2 and its YVMA mutant while maintaining oral bioavailability and sparing EGFR activity.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!